Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02713607

Lipidome and Microbiome Profile of Acne

Lipidome and microbiome analysis in subjects with acne on doxycycline. Investigators will look at the skin lipidome, blood lipidome, gut micro biome and skin micro biome.

Investigators will look at the changes between acne subjects and control participants, but also the changes that occur after the use of antibiotics and how this is altered.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

15 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

UC Davis Dept of Dermatology

Sacramento, California, 95816, United States

About this study

We will look at acne subjects, and controls.

We will look at four things

  • skin lipidome
  • skin microbiome
  • gut microbiome
  • blood lipidome

Investigators will assess this in acne participants before and after doxycycline and compare them to controls.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 15 and older
  • Subjects/parents/legal guardian is able to read and comprehend study procedure and consent forms.
  • Have already been prescribed Doxycycline by their physician for acne or to be eligible to be prescribed Doxycycline for acne
  • Have acne that is diagnosed by a board certified dermatologist.

Exclusion criteria

  • Those who have received systemic antibiotics within four weeks of starting the study.
  • Those who have received systemic isotretinoin within six weeks of starting the study.
  • Those with seborrheic dermatitis, rosacea, or polycystic ovary syndrome
  • Those who are pregnant, prisoners or cognitively impaired.
  • Those subjects who are currently using proton pump inhibits (as studies have shown this may impact the gut microbiome) (4)
  • Those who have a BMI greater than >30 kg/m2, as studies have shown a reduction in the variability of intestinal microbes within this population (5).
  • Those who have initiated or changed brand of oral contraceptive pill within 4 weeks of starting the study.
  • Those who have autoimmune disorders as this group has been shown to have an altered microbiome (6)
  • Those who have diabetes (6), immunodeficiencies (7), inflammatory bowel disease (6), hypercholesterolemia, as these groups have been shown to have altered gut microbiomes
  • Those who have taken oral probiotic supplements (8) within 4 weeks of starting the study
  • Given the nature of the instructions that need to be adhered to for accurate collection of samples and this data, non-English speaking individuals will be excluded from this pilot study.
  • Allergies to the tetracycline group of antibiotics
  • Those who do not fit the inclusion criteria

Treatment and study plan

Doxycycline

Drug

Given doxycycline to acne subjects

Primary outcomes

  1. Change in the diversity of the gut microbiome in those with and without acne.

    Time frame: 2 years

    The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome.

  2. Change in the diversity of the gut microbiome before and after the treatment of doxycycline in those with acne.

    Time frame: 2 years

    The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome.

Secondary outcomes

  1. Change in global acne grade score

    Time frame: 2 years

  2. Change in the investigator global assessment of acne

    Time frame: 2 years

  3. Change in the lesion count of inflammatory and non-inflammatory lesions

    Time frame: 2 years

  4. Change in the diversity of the skin microbiome in those with and without acne

    Time frame: 2 years

    The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome.

  5. Change in the diversity of the skin microbiome before and after treatment with doxycycline in those with acne

    Time frame: 2 years

    The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome.

  6. Change in the diversity of the skin lipidome in those with and without acne

    Time frame: 2 years

    The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids.

  7. Change in the skin lipidome before and after treatment with doxycycline in those with acne

    Time frame: 2 years

    The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids.

  8. Change in the diversity of the blood lipidome in those with and without acne

    Time frame: 2 year

    The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids.

  9. Change in the blood lipidome before and after treatment with doxycycline in those with

    Time frame: 2 years

    The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids.

Sponsors and collaborators

Lead sponsor

University of California, Davis

Other

Registry information

Important dates

Study start
2016
Primary completion
2027
Study completion
2027
First posted
Mar 21, 2016
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.